Cargando…
Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects
BACKGROUND: Fosaprepitant, an NK(1) receptor antagonist, inhibits and induces cytochrome P450 3A4 (CYP3A4) as its substrate. Contrarily dexamethasone is metabolized by CYP3A4. Therefore, in combination therapy wherein both agents interact with each other, it is recommended that the dexamethasone dos...
Autores principales: | Shimamoto, Fukutaro, Goto, Masahiro, Terazawa, Tetsuji, Asaishi, Ken, Miyamoto, Takahiro, Higuchi, Kazuhide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286666/ https://www.ncbi.nlm.nih.gov/pubmed/33773552 http://dx.doi.org/10.31557/APJCP.2021.22.3.871 |
Ejemplares similares
-
Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant
por: Olver, Ian N
Publicado: (2008) -
Prognostic Impact of Ectopic Fat Deposition within Psoas Muscle in Stage IV Gastric Cancer Patients Undergoing Systemic Chemotherapy
por: Ikegami, Takako, et al.
Publicado: (2022) -
Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010) -
Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
por: Candelario, Nellowe, et al.
Publicado: (2016) -
Olanzapine: An Antiemetic Option for Chemotherapy-Induced Nausea and Vomiting
por: Brafford, Megan V., et al.
Publicado: (2014)